Health Condition 1: M255- Pain in joint
Conditions
Interventions
Intervention1: PeaNoc-XL 400mg: Standard Treatment + PeaNoc-XL 400mg
Intervention2: PeaNoc-XL
(palmitoylethanolamide 400mg and astaxanthin 1mg): PeaNoc-XL (palmitoylethanolamide 400mg and astaxanthin
Sponsors
Apex Laboratories Pvt Ltd
SRM INSTITUTE OF SCIENCE AND TECHNOLOGY
Eligibility
Inclusion criteria
Inclusion criteria: -Patients with DAS 28 (Disease Activity Score) score greater than or equal to 3.2 -Willingness to provide written informed consent to participate in the study. -Patients understanding the nature and purpose of the study and who are willing to comply with study procedures.
Exclusion criteria
Exclusion criteria: -Patients who are taking other NSAID /Pain killers other than standard drug -Abnormal results on Liver function test -Patients with diabetic neuropathy -Patients with severe renal, hepatic, cardiac, gastrointestinal, neurological, hematological or respiratory disorder
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Hematological investigations: Complete Blood count will be assessed before and after the study. 2. Biochemical investigations: Serum creatinine, Liver function tests will be assessed before and after the study. 3. Inflammatory cytokines (IL-1, IL-6, and TNF-α), C - reactive protein (CRP) and Erythrocyte sedimentation rate (ESR) will be assessed before and after the study. 4. DAS 28 score will be assessed before and after the study.Timepoint: 06 months | — |
Secondary
| Measure | Time frame |
|---|---|
| To assess adverse drug reactions during the study period Timepoint: 06 months | — |
Countries
India
Contacts
Public ContactMothishwaran B
SRM INSTITUTE OF SCIENCE AND TECHNOLOGY
Outcome results
None listed